Low molecular weight heparins in the treatment of lung cancer

Bibliography

• Pignon JP, Tribodet H, Scagliotti GV, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9
   PubMed Web of Science ®Google Scholar
• Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 1865;3:659-712
   Google Scholar
• Hettiarachchi RJ, Lok J, Prins MH, Buller HR. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998;83(1):180-5
   PubMed Web of Science ®Google Scholar
• Saba HI, Khalil FK, Morelli GA, Thromboembolism preceding cancer: a correlation study. Am J Hematol 2003;72(2):109-14
   PubMed Web of Science ®Google Scholar
• van der Heiden PL, Prins MH, de Monye W, Pulmonary embolism as a first clinical sign of occult malignancy: a prospective follow-up study. Thromb Haemost 2006;95(3):584-5
   PubMed Web of Science ®Google Scholar
• El Sakka K, Gambhir RP, Halawa M, Association of malignant disease with critical leg ischaemia. Br J Surg 2005;92(12):1498-501
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindier MJ, Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4(3):529-35
   PubMed Web of Science ®Google Scholar
• Tagalakis V, Levi D, Agulnik JS, High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007;2(8):729-34
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6):715-22
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846-50
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91
   PubMed Web of Science ®Google Scholar
• Numico G, Garrone O, Dongiovanni V, Silvestris N. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103(5):994-9
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Dao V, Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 2011;22(2):86-91
   PubMed Web of Science ®Google Scholar
• Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001;106(1-2):25-32
   PubMed Web of Science ®Google Scholar
• Varon D, Brill A. Platelets cross-talk with tumor cells. Haemostasis 2001;31(Suppl 1):64-6
   PubMedGoogle Scholar
• Marinho FC, Takagaki TY. Hypercoagulability and lung cancer. J Bras Pneumol 2008;34(5):312-22
   PubMedGoogle Scholar
• Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000;85(9):967-72
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162(15):1729-35
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A, American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25(34):5490-505
   PubMed Web of Science ®Google Scholar
• Akl EA, Barba M, Rohilla S, Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008;27:21
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10(10):943-9
   PubMed Web of Science ®Google Scholar
• Albert-Weil J, Nehorias J. Two cases of neoplasms not justified for classical therapy, treated with intravenous injections of heparin and intramuscular injections of leech extracts. Rev Pathol Gen Physiol Clin 1954;54(660):1014-20
   PubMedGoogle Scholar
• Prandoni P, Lensing AW, Piccioli A, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-8
   PubMed Web of Science ®Google Scholar
• von Delius S, Ayvaz M, Wagenpfeil S, Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98(2):434-9
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Utkan G, Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95(6):507-12
   PubMed Web of Science ®Google Scholar
• Dolovich LR, Ginsberg JS, Douketis JD, A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181-8
   PubMed Web of Science ®Google Scholar
• Lebeau B, Chastang C, Brechot JM, Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994;74(1):38-45
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Ilan N, Nadir Y, Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007;120(Suppl 2):S112-20
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108(3):341-7
   PubMed Web of Science ®Google Scholar
• Borsig L, Wong R, Feramisco J, Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98(6):3352-7
   PubMed Web of Science ®Google Scholar
• Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004;9(3):205-13
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80(1):10-23
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Papageorgiou C, Hatmi M, Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 2008;36(3-4):204-11
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123-9
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22(10):1944-8
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM, The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23(10):2130-5
   PubMed Web of Science ®Google Scholar
• Sideras K, Schaefer PL, Okuno SH, Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81(6):758-67
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O, A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2(8):1266-71
   PubMed Web of Science ®Google Scholar
• van Doormaal FF, Di Nisio M, Otten HM, Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29(15):2071-6
   PubMed Web of Science ®Google Scholar
• Dingemans AC, Smit EF, van der Heijden E, A randomised phase III study of adjuvant chemotherapy in PET-selected patients with completely resected non-small cell lungs cancer (NSCLC): NVALT 8. Ann Oncol 2008;19:Suppl 8, pg viii97
   Google Scholar
• Griffiths GO, Burns S, Noble SI, FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 2009;9:355
   PubMed Web of Science ®Google Scholar